Tandem Diabetes Care | TNDM - Assets


Tandem Diabetes Care reported $874.65M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Abbott USD 84.18B 182M Sep/2025
Align Technology USD 6.23B 14.46M Sep/2025
AtriCure USD 635.44M 26.59M Sep/2025
Baxter International USD 21.07B 21M Sep/2025
Becton, Dickinson and Co. USD 55.32B 423M Sep/2025
Boston Scientific USD 42.71B 1.15B Sep/2025
Cooper Companies USD 12.39B 18.1M Sep/2025
Dexcom USD 7.5B 173M Sep/2025
Edwards Lifesciences USD 13.27B 216.5M Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Globus Medical USD 5.1B 134.55M Sep/2025
ICU Medical USD 4.1B 4.49M Sep/2025
Insulet USD 3.03B 439.9M Sep/2025
Integra LifeSciences USD 3.65B 21.45M Sep/2025
Intuitive Surgical USD 20.46B 1.11B Dec/2025
J&J USD 192.82B 573M Sep/2025
Masimo USD 1.82B 585.1M Sep/2025
Medtronic USD 90.97B 708M Jun/2025
Merit Medical Systems USD 2.63B 44.95M Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Stryker USD 47.84B 787M Dec/2025
Tandem Diabetes Care USD 874.65M 1.08M Sep/2025
Teleflex USD 7.87B 496.72M Sep/2025
Zimmer Biomet Holdings USD 23.49B 622.9M Sep/2025